Active Infection & Immunity Lungs & Breathing

Mathematically modelling tuberculosis: using lung scans to map infection, and a hybrid individual-based model to simulate infection and treatment

In plain English

AI plain-English summary

A lung scan could soon tell doctors exactly which antibiotics a tuberculosis patient needs, and for how long. TB is now the world’s biggest infectious disease killer, yet treatment protocols remain rigid—doctors adjust doses only by patient weight, ignoring how diabetes, HIV, or the extent of lung damage alter infection dynamics. This project aims to close that gap by combining AI analysis of lung scans with mathematical models that simulate how TB bacteria and the immune system interact inside an individual patient. If the models prove accurate, doctors could feed a patient’s CT scan into an algorithm that maps infection severity and location, then run simulations to test different drug combinations and durations. The result would be personalised treatment: some patients would need shorter, cheaper regimens with fewer side effects, while others would receive adjusted doses to prevent relapse and reduce the risk of antibiotic resistance emerging. The work uses lung scans and clinical data from a South African trial, and the researcher will collaborate with biologists to incorporate the effects of diabetes and HIV on infection dynamics.

View original technical description
Tuberculosis (TB) is an infectious disease that usually affects the lungs. It can develop when bacteria spread through droplets in the air. In the past TB or "consumption" was a major cause of death worldwide. After the discovery of antibiotics and general improvement in living conditions, prevalence of the disease fell. However, since the 1980s cases have been rising again. TB is now the biggest infectious disease killer (above HIV/AIDS and now COVID-19). This project seeks to take a step forward in personalising TB treatment. Currently with treatment for TB disease, doctors must follow rigid treatment protocols that only allow for variations in patients' weights. These treatment regimens were defined years ago when very little was understood about this disease. We now know more about TB bacteria and how the infection dynamics can change depending on particular patients' immune responses. For example, people who have diabetes and/or HIV tend to have more complex and severe TB disease. We also know that the severity of infection, i.e. the amount of lung tissue affected, plays a part in how successful treatment will be. This project seeks to group TB patients according to their bacterial burden, i.e. how much infection is present, and the presence of any other conditions (such as diabetes or HIV) that could make their TB disease more complex, in order to find optimal ways of treating them. I will use a collection of lung scans taken from a clinical trial in South Africa to develop Artificial Intelligence (AI) algorithms to automatically identify TB infection in patients. This algorithm will be able to identify where in the lungs the infection appears and how severe it is. This will mean that in future TB doctors could take an individual TB patient's lung scan and feed it into the AI algorithm to automatically map that patient's TB infection onto a computer. Once on the computer, I will use mathematical modelling to simulate what would happen in that patient's lungs (also taking into account their particular immune response, by factoring in whether they are diabetic or HIV-positive). I have already developed mathematical models that are capable of simulating a typical immune response during TB infection and will work with relevant biologists to integrate the differences seen in infection dynamics when patients are also diabetic/HIV-positive. Building mathematical models of this type is complex and there are many unknowns, this is why I will work closely with my biological collaborators to ensure that the latest laboratory data is used to quantify the processes involved. I will also work with mathematical/computational colleagues to use relevant techniques to help with model development, and to test how accurate the models are. I will also use additional data from the South African clinical trial to test model predictions. Once I am confident that the AI algorithms and models are robust, I will work with doctors to try to find more patient-specific treatment protocols. This will mean in future that some patients won't need as much treatment (hence cutting costs and reducing side-effects for these patients), and some will need variations in the antibiotic combinations/doses that are currently prescribed. Ultimately this will help to increase treatment success, prevent future TB relapses, and reduce the chance of antibiotic resistance emerging.

View the original record at the funder ↗

Researchers

Ruth Bowness (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

A novel hybrid discrete-continuum cellular automaton model to study tuberculosis disease progression and treatment
Use of AI/ML and Digital Health tools in tuberculosis drug development - a feasibility study
Mathematical modelling and spatial data analysis to inform TB care and control strategies in high TB incidence settings
Spatially-resolved PKPD modelling for optimised treatment of central nervous system infection due to Mycobacterium tuberculosis
Within-Host Individual-Based Model for Diabetic Tuberculosis Patients

Original classification

Fellowship

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.